Comparison of a Slow-Release Formulation of Oxprenolol with Conventional Oxprenolol in the Treatment of Hypertension

1976 ◽  
Vol 51 (s3) ◽  
pp. 559s-561s
Author(s):  
K. P. O'brien ◽  
E. J. W. Stephens
Keyword(s):  
Blood Pressure ◽  
Patient Compliance ◽  
Slow Release ◽  
Severe Hypertension ◽  
Total Daily Dose ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
Daily Dose ◽  
Treatment Of Hypertension

1. Patients with moderate to severe hypertension were studied during a 12 weeks period, while taking a slow-release formulation of oxprenolol once daily, in a dose equal to their previous total daily dose of oxprenolol given in divided doses. 2. There were no significant differences between blood pressure at the beginning and end of the 12 weeks period. 3. Once-daily dosage offers advantages of patient compliance.

Experiences with Metoprolol Durules®, A Slow-Release Formulation in Hypertension

1980 ◽  
Vol 8 (1) ◽  
pp. 44-49 ◽  
Author(s):  
Jaakko Tuomilehto ◽  
Aulikki Nissinen
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Moderate Hypertension ◽  
Antihypertensive Effect ◽  
Slow Release ◽  
Final Dose ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
The Mean

The antihypertensive effect and the tolerability of metoprolol Durules® have been studied in fifty-five patients with mild to moderate hypertension. The patients' diastolic blood pressure was ≥95 mm Hg in order to qualify for entry. Thirty-seven out of fifty-three patients completing the study (70%) were treated with metoprolol Durules® monotherapy throughout the study. The mean blood pressure was reduced from 153/101 to 138/92 mm Hg after metoprolol Durules® compared to placebo (p < 0.001). Twenty-seven patients received one Durules® daily and ten patients received two Durules® daily as the final dose. Of the sixteen patients not responding on metoprolol Durules®, six patients achieved satisfactory control, i.e. a diastolic blood pressure below 95 mm Hg, when given 200 mg metoprolol + 25 mg hydrochlorothiazide (HCT). The results indicate that most patients with, mild or moderate hypertension can be controlled with metoprolol Durules® monotherapy given once daily. The addition of HCT gives a significant benefit in moderate hypertension, where metoprolol monotherapy is not sufficient.

Once Daily Administration of Pindolol in the Treatment of Hypertension

1973 ◽  
Vol 1 (2) ◽  
pp. 465-469
Author(s):  
R C Dhatariya ◽  
A J Blowers
Keyword(s):  
Blood Pressure ◽  
Pressure Control ◽  
Moderate Essential Hypertension ◽  
Loss Of Control ◽  
Once Daily ◽  
Daily Dose ◽  
Treatment Of Hypertension ◽  
Previously Treated Patients ◽  
Previously Treated ◽  
Daily Dose Regimen

An open study was carried out in general practice on patients with mild to moderate essential hypertension to assess the effectiveness of treatment with pindolol on a single daily dose regimen. In twenty-two previously untreated cases given a single daily dosage of pindolol (mean 13.0 mg, range 5 mg −30 mg), adequate blood pressure control was achieved within five weeks and maintained in the nineteen patients examined at Week 25. Of eleven previously treated patients whose blood pressure was adequately controlled by divided daily doses of pindolol, a change-over to a single daily dosage of pindolol (mean 13.2 mg, range 10 mg − 20 mg) did not result in any loss of control over a twenty-five week study period. Few side-effects were reported, and only one patient was withdrawn from the study.

scholarly journals Once Daily Beta-Blocker in Hypertension – Oxprenolol Slow-Release

1981 ◽  
Vol 9 (1) ◽  
pp. 6-11
Author(s):  
R D Gordon ◽  
M Ziesak ◽  
W S Rowe ◽  
C R Strakosch ◽  
G Row
Keyword(s):  
Blood Pressure ◽  
Pulse Rate ◽  
Beta Blocker ◽  
Slow Release ◽  
Beta Blockers ◽  
Once Daily ◽  
Treatment Of Hypertension ◽  
Blood Pressures ◽  
Order Of Administration ◽  
At Home

In a within-patient comparison of conventional oxprenolol administered twice daily with slow-release oxprenolol administered once daily in the treatment of hypertension, twenty patients previously responsive to beta-blockers took each formulation for 4 weeks, after wash-out periods off beta-blocker of 2 weeks' duration. The order of administration of the two forms was randomized, and sixteen patients continued medication with cyclopenthiazide 0.5 mg daily. Blood pressure levels at the end of the 4-week treatment periods were compared with levels at the end of the preceding 2-week wash-out periods. Both formulations lowered blood pressure and pulse rate significantly. There was no difference in their effects on pulse rate or on blood pressure, whether measured by the doctors using standard sphygmomanometers or by the hypertension sister using a random-zero sphygmomanometer. In four patients who measured their own blood pressures at home each morning (before medications), afternoon and night, mean levels were similar with the two formulations. Both formulations were very well tolerated.

THEOPHYLLINE ATTENUATION OF AIRWAY RESPONSES TO ALLERGEN: COMPARISON WITH CROMOLYN METERED-DOSE INHALER

PEDIATRICS ◽  
1996 ◽  
Vol 98 (2) ◽  
pp. 341-341
Author(s):  
Robert A. Wood
Keyword(s):  
Slow Release ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Release Formulation ◽  
Once Daily ◽  
Slow Release Formulation ◽  
Metered Dose ◽  
Airway Responses

Theophylline administered as a once daily slow-release formulation was as effective as cromolyn delivered by an MDI in attenuating airway responses to inhaled allergen.

Twenty-Four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension

1991 ◽  
Vol 5 (4) ◽  
pp. 701-707 ◽  
Author(s):  
Alain G. Dupont ◽  
Jean M. Coupez ◽  
Patrick Jensen ◽  
Renée Coupez-Lopinot ◽  
Danny F. Schoors ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ambulatory Blood Pressure ◽  
Moderate Hypertension ◽  
Slow Release ◽  
Pressure Profile ◽  
Release Formulation ◽  
Slow Release Formulation ◽  
Blood Pressure Profile

scholarly journals Mesalazine (5-aminosalicylic acid) induced chronic hepatitis

Gut ◽  
1999 ◽  
Vol 44 (6) ◽  
pp. 886-888 ◽  
Author(s):  
P Deltenre ◽  
A Berson ◽  
P Marcellin ◽  
C Degott ◽  
M Biour ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Adverse Effects ◽  
Liver Dysfunction ◽  
Liver Enzymes ◽  
Slow Release ◽  
Aminosalicylic Acid ◽  
Safe Alternative ◽  
Release Formulation ◽  
Slow Release Formulation

BACKGROUNDTreatment of ulcerative colitis or Crohn’s disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow release formulation of 5-aminosalicylic acid, was expected to be a safe alternative. However, several cases of acute hepatitis have been reported.CASE REPORTA 65 year old man had increased liver enzymes, anti-nuclear and anti-smooth muscle autoantibodies and IgG levels, and lesions of chronic hepatitis after 21 months of mesalazine treatment. Although liver dysfunction had been identified eight months earlier, simvastatin rather than mesalazine had been withdrawn, without any improvement. In contrast, liver enzyme and IgG levels became normal and autoantibodies disappeared after discontinuation of mesalazine administration.CONCLUSIONContrary to initial expectations, mesalazine can cause most of the sulphasalazine induced adverse effects, and hepatic side effects may be almost as frequent. When liver dysfunction occurs, mesalazine administration should be discontinued to avoid the development of chronic hepatitis and liver fibrosis.

Pharmacokinetics of a Slow-Release Formulation of Soybean Isoflavones in Healthy Postmenopausal Women

2005 ◽  
Vol 53 (6) ◽  
pp. 1938-1944 ◽  
Author(s):  
Kenneth D. R. Setchell ◽  
Amnon Brzezinski ◽  
Nadine M. Brown ◽  
Pankaj B. Desai ◽  
Murad Melhem ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Slow Release ◽  
Release Formulation ◽  
Soybean Isoflavones ◽  
Slow Release Formulation
Sign in / Sign up

Export Citation Format

Share Document